

Claims

1. An isolated polypeptide having the sequence of DSP-2 recited in SEQ ID NO:2, or a variant thereof that differs in one or more amino acid deletions, additions, insertions or substitutions at no more than 50% of the residues in SEQ ID NO:2, such that the polypeptide retains the ability to dephosphorylate an activated MAP-kinase.

2. An isolated polynucleotide that encodes at least ten consecutive amino acids of a polypeptide having a sequence corresponding to SEQ ID NO:2.

3. An isolated polynucleotide that encodes at least fifteen consecutive amino acids of a polypeptide having a sequence corresponding to SEQ ID NO:2.

4. An expression vector comprising a polynucleotide according to claim

2 or 3.

5. A host cell transformed or transfected with an expression vector according to claim 4.

6. An isolated polynucleotide that encodes a polypeptide according to claim 1.

7. A polynucleotide according to claim 6, comprising the sequence recited in SEQ ID NO:1.

8. An expression vector comprising a polynucleotide according to claim 6.

9. A host cell transformed or transfected with an expression vector according to claim 8.

0097ED-92E2560

10. An antisense polynucleotide comprising at least 15 consecutive nucleotides complementary to a polynucleotide according to claim 6.

11. An isolated polynucleotide that detectably hybridizes to the complement of the sequence recited in SEQ ID NO:1 under conditions that include a wash in 0.1X SSC and 0.1% SDS at 60 °C for 15 minutes.

~80-85%

12. An expression vector comprising a polynucleotide according to claim 10 or claim 11.

13. A host cell transformed or transfected with an expression vector according to claim 12.

14. A method of producing a DSP-2 polypeptide, comprising the steps of:

- (a) culturing a host cell according to claim 9 under conditions that permit expression of the DSP-2 polypeptide; and
- (b) isolating DSP-2 polypeptide from the host cell culture.

15. An isolated antibody, or antigen binding fragment thereof, that specifically binds to a DSP-2 polypeptide having the sequence of SEQ ID NO:2.

16. An antibody or fragment thereof according to claim 15, wherein the antibody is a monoclonal antibody.

17. A pharmaceutical composition comprising an antibody or fragment thereof according to claim 15 in combination with a physiologically acceptable carrier.

18. A method for detecting DSP-2 expression in a sample, comprising:

- (a) contacting a sample with an antibody or an antigen-binding fragment thereof according to claim 15, under conditions and for a time sufficient to allow formation of an antibody/DSP-2 complex; and

0097376-034600

(b) detecting the level of antibody/DSP-2 complex, and therefrom detecting the presence of DSP-2 in a sample.

19. A method according to claim 18, wherein the antibody is linked to a support material.

20. A method according to claim 18, wherein the antibody is linked to a detectable marker.

21. A method according to claim 18, wherein the sample is a biological sample obtained from a patient.

22. A method for detecting DSP-2 expression in a sample, comprising:

(a) contacting a sample with an antisense polynucleotide according to claim 10 or claim 11; and

(b) detecting in the sample an amount of DSP-2 polynucleotide that hybridizes to the antisense polynucleotide, and therefrom detecting DSP-2 expression in the sample.

23. A method according to claim 22, wherein the amount of DSP-2 polynucleotide that hybridizes to the antisense polynucleotide is determined using polymerase chain reaction.

24. A method according to claim 22, wherein the amount of DSP-2 polynucleotide that hybridizes to the antisense polynucleotide is determined using a hybridization assay.

25. A method according to claim 22, wherein the sample comprises an RNA or cDNA preparation.

009750-922550

26. A method for screening for an agent that modulates DSP-2 activity, comprising the steps of:

(a) contacting a candidate agent with a polypeptide according to claim 1, under conditions and for a time sufficient to permit interaction between the polypeptide and candidate agent; and

(b) subsequently evaluating the ability of the polypeptide to dephosphorylate a DSP-2 substrate, relative to a predetermined ability of the polypeptide to dephosphorylate the DSP-2 substrate in the absence of candidate agent;

and therefrom identifying an agent that modulates DSP-2 activity.

27. A method according to claim 26, wherein the DSP-2 substrate is a MAP-kinase.

28. A method according to claim 26, wherein the candidate agent is a small molecule.

29. A method according to claim 26, wherein the small molecule is present within a combinatorial library.

30. A method for screening for an agent that modulates DSP-2 activity, comprising the steps of:

(a) contacting a candidate agent with a cell comprising a DSP-2 promoter operably linked to a polynucleotide encoding a detectable transcript or protein, under conditions and for a time sufficient to permit interaction between the promoter and candidate agent; and

(b) subsequently evaluating the expression of the polynucleotide, relative to a predetermined level of expression in the absence of candidate agent;

and therefrom identifying an agent that modulates DSP-2 activity.

31. A method according to claim 30, wherein the polynucleotide encodes a DSP-2 polypeptide.

009750-942560

32. A method according to claim 30, wherein the polynucleotide encodes a reporter protein.

33. A method for modulating a proliferative response in a cell, comprising contacting a cell with an agent that modulates DSP-2 activity.

34. A method for modulating differentiation of a cell, comprising contacting a cell with an agent that modulates DSP-2 activity.

35. A method for modulating survival of a cell, comprising contacting a cell with an agent that modulates DSP-2 activity.

36. A method according to any one of claims 33-35, wherein the agent modulates a pattern of gene expression.

37. A method according to any one of claims 33-35, wherein the cell displays contact inhibition of cell growth.

38. A method according to any one of claims 33-35, wherein the cell displays anchorage independent growth.

39. A method according to any one of claims 33-35, wherein the cell displays an altered intercellular adhesion property.

40. A method according to claim 35, wherein the agent modulates apoptosis.

41. A method according to claim 35, wherein the agent modulates the cell cycle.

009750-922560

42. A method according to claim 32, wherein the cell is present within a patient.

43. A method for treating a patient afflicted with a disorder associated with DSP-2 activity, comprising administering to a patient a therapeutically effective amount of an agent that modulates DSP-2 activity.

44. A method according to claim 43, wherein the disorder is selected from the group consisting of cancer, graft-versus-host disease, autoimmune diseases, allergies, metabolic diseases, abnormal cell growth, abnormal cell proliferation and cell cycle abnormalities.

45. A method for inhibiting rejection of transplanted tissue in a patient, comprising administering to a patient a therapeutically effective amount of an agent that modulates DSP-2 activity.

46. A DSP-2 substrate trapping mutant polypeptide that differs from the sequence recited in SEQ ID NO:2 in one or more amino acid deletions, additions, insertions or substitutions at no more than 50% of the residues in SEQ ID NO:2, such that the polypeptide binds to a substrate with an affinity that is not substantially diminished relative to DSP-2, and such that the ability of the polypeptide to dephosphorylate a substrate is reduced relative to DSP-2.

47. A substrate trapping mutant polypeptide according to claim 46, wherein the polypeptide contains a substitution at position 73 or position 104 of SEQ ID NO:2.

48. A method for screening a molecule for the ability to interact with DSP-2, comprising the steps of:

- (b) detecting the presence or absence of binding of the candidate molecule to the polypeptide, and therefrom determining whether the candidate molecule interacts with DSP-2.

49. A method according to claim 48, wherein the step of detecting comprises an affinity purification step.

50. A method according to claim 48, wherein the step of detecting comprises a yeast two hybrid screen or a screen of a phage display library.